TABLE 2

Hemodynamic parameters

ControlSTZSTZ-IRB
Systolic function
    LVP (mmHg)107.5 ± 6.867.1 ± 3.1*69.6 ± 2.2*
    dP/dt max (mmHg/s)6,021 ± 6093,556 ± 323*4,085 ± 379*
    Ejection fraction (%)61.7 ± 1.948 ± 555 ± 4
    Ees (mmHg/μl)1.67 ± 0.080.95 ± 0.07*1.45 ± 0.03§
Diastolic function
    LVEDP (mmHg)3.5 ± 0.611.8 ± 2.6*7.3 ± 1.2*§
    dP/dt min (mmHg/s)−5,402 ± 547−3,270 ± 323*−3,764 ± 411*
    Diastolic stiffness (ml−1)0.038 ± 0.0030.109 ± 0.009*0.059 ± 0.004*§
Cardiac performance
    Heart rate (bpm)434 ± 23311 ± 35*371 ± 12
    Cardiac output (μl/min)16,053 ± 6358,310 ± 825*11,590 ± 1,071*§
    Stroke volume (μl)36.9 ± 1.227.7 ± 2.631.9 ± 5.2
    Volume end diastolic (μl)63.9 ± 464 ± 369.7 ± 5
    Volume end systolic (μl)23.1 ± 836 ± 837 ± 8
    Afterload (mmHg/μl)2.9 ± 0.082.7 ± 0.052.3 ± 0.04§
  • Hemodynamic function of controls, mice with STZ-induced diabetes, and diabetic mice treated with irbesartan (STZ-IRB).

  • *

    * P < 0.05 vs. controls;

  • §

    § P < 0.05 vs. STZ.